Tag Archives: Mesothelioma

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Bristol Myers Squibb’s Opdivo-Yervoy combo helps mesothelioma patients live longer

Bristol-Myers Squibb’s Opdivo-Yervoy combo is awaiting some critical decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication, too. The immuno-oncology duo topped chemo at extending the lives of phase 3 trial patients with previously untreated malignant pleural mesothelioma (MPM), the company said Monday. The rare cancer,… Read More »

GM’s Liability for Mesothelioma Claims, Much More than Original Estimate

GM’s Liability for Mesothelioma Claims, Much More than Original EstimateDecember 3, 2010 In an attempt to decipher the extent of liability General Motors Corp will be under with mesothelioma claims, creditors sought out and received information from the company and other entities. This information was obtained with permission from U.S. Bankruptcy Judge Robert Gerber, in… Read More »